The second one is an anti-VEGFR2 antibody, blocking VEGF ligands from activating the VEGFRs, thereby inhibiting angiogenesis, and it is approved for therapy of gastric cancer (2014), NSCLC, including EGFR-mutated and metastatic forms (2014, 2020), CRC (2015), and HCC (2019) [225,226]. Here, VEGFA is linked to non-small cell lung carcinoma.